Iovance Surges After UBS Raises Target

Iovance Biotherapeutics shares jumped 32.9% week-on-week after UBS doubled its price target to $4 from $2 while keeping a neutral rating, ahead of the company's participation at Barclays' 28th Annual Global Healthcare Conference on March 11. The firm reported a 5% wider full-year net loss of $390.98 million versus $372 million in 2024, with total revenues rising 60.6% to $263.5 million; Q4 net loss narrowed to $71.9 million and Q4 revenue increased to $86.7 million.